Table 2.
Plasma levels of estrone, estrone sulphate and SHBG among 339 never and past users of HRT as percentage difference in hormonal measurements in relation to CYP19A1 polymorphisms
| Genotype | n (%) | Estrone | P-valueb | Estrone sulphate | P-valueb | SHBG | P-valueb |
|---|---|---|---|---|---|---|---|
| n = 339 | ∆ (95 % CI)a | ∆ (95 % CI)a | ∆ (95 % CI)a | ||||
| rs10519297 | |||||||
| AA | 81 (24) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| AG | 187 (55) | 8 (−4;21) | 0.35 | 10 (−1;21) | 0.05 | −5 (−14;6) | 0.66 |
| GG | 71 (21) | 1 (−13;16) | 16 (3;31) | −2 (−14;11) | |||
| AG + GG | 258 (56) | 6 (−6;18) | 0.34 | 12 (1;23) | 0.03 | −4 (−13;6) | 0.44 |
| rs749292 | |||||||
| GG | 101 (30) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| AG | 169 (50) | −5 (−15;6) | 0.62 | −11 (−19;-2) | 0.007 | −3 (−12;7) | 0.07 |
| AA | 69 (20) | −5 (−17;9) | −16 (−26;-6) | 11 (−2;26) | |||
| AG + AA | 238 (70) | −5 (−14;5) | 0.33 | −12 (−20;-4) | 0.004 | 1 (−8;11) | 0.82 |
| rs1062033 | |||||||
| CC | 88 (26) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| CG | 180 (53) | −2 (−13;10) | 0.53 | −10 (−19;-1) | 0.01 | −1 (−11;9) | 0.45 |
| GG | 71 (21) | −7 (−20;6) | −16 (−26;-6) | 6 (−7;21) | |||
| CG + GG | 251 (74) | −4 (−14;7) | 0.51 | −12 (−20;-3) | 0.007 | 1 (−9;11) | 0.88 |
| rs10046 | |||||||
| AA | 93 (27) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| AG | 177 (52) | 2 (−9;15) | 0.58 | 4 (−5;15) | 0.26 | −1 (−10;10) | 0.94 |
| GG | 69 (20) | −4 (−17;10) | 11 (−2;25) | −2 (−14;11) | |||
| AG + GG | 246 (73) | 0 (−10;12) | 0.93 | 6 (−3;16) | 0.21 | −1 (−10;9) | 0.82 |
| rs4646 | |||||||
| CC | 186 (55) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| CA | 133 (39) | 3 (−7;14) | 0.68 | 5 (−3;15) | 0.38 | −4 (−13;5) | 0.59 |
| AA | 20 (6) | −6 (−23;16) | 10 (−8;31) | −5 (−21;15) | |||
| CA + AA | 153 (45) | 2 (−8;12) | 0.73 | 6 (−3;15) | 0.18 | −4 (−13;4) | 0.30 |
| rs6493487 | |||||||
| AA | 203 (60) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| GA | 127 (38) | −5 (−14;5) | 0.27 | 4 (−4;14) | 0.63 | −5 (−13;4) | 0.37 |
| GG | 9 (3) | −19 (−40;9) | 0 (−23;29) | −14 (−34;13) | |||
| GA + GG | 136 (41) | −6 (−15;4) | 0.23 | 4 (−4;13) | 0.36 | −5 (−13;3) | 0.22 |
| rs2008691 | |||||||
| AA | 220 (65) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| GA | 109 (32) | 4 (−6;15) | 0.35 | 3 (−6;12) | 0.83 | 2 (−7;12) | 0.17 |
| GG | 10 (3) | 21 (−9;60) | 0 (−21;28) | 27 (−1;64) | |||
| GA + GG | 119 (35) | 5 (−4;16) | 0.29 | 2 (−6;12) | 0.57 | 4 (−5;14) | 0.37 |
| rs3751591 | |||||||
| TT | 241 (71) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| TC | 90 (27) | 2 (−9;13) | 0.55 | 1 (−8;10) | 0.50 | 1 (−9;11) | 0.09 |
| CC | 8 (2) | 19 (−13;63) | 18 (−10;54) | 38 (4;83) | |||
| CC vs. TT + TC | 8 (2) | 18 (−14;62) | 0.29 | 17 (−10;53) | 0.24 | 37 (4;82) | 0.03 |
| rs2445762 | |||||||
| TT | 175 (52) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| TC | 142 (42) | −3 (−12;7) | 0.71 | −1 (−9;8) | 0.71 | −3 (−19;16) | 0.53 |
| CC | 22 (6) | −7 (−24;13) | −7 (−21;10) | −5 (−13;4) | |||
| TC + CC | 164 (48) | −3 (−12;6) | 0.47 | −2 (−10;6) | 0.63 | −5 (−13;4) | 0.27 |
| rs11070844 | |||||||
| CC | 267 (79) | 0 (ref.) | 0 (ref.) | 0 (ref.) | |||
| TC | 68 (20) | 17 (4;31) | 0.03 | 13 (2;25) | 0.04 | 6 (−5;18) | 0.20 |
| TT | 4 (1) | 16 (−26;79) | 23 (−16;79) | 36 (−9;103) | |||
| TC + TT | 72 (21) | 17 (4;31) | 0.009 | 14 (3;25) | 0.01 | 7 (−3;19) | 0.18 |
SHBG Sex-hormone binding globulin
Δ Percentage difference in hormonal measurements compared to WT
aAdjusted for age, smoking (never, past, current), alcohol intake (increment of 10 g per day) and BMI (kg/m2) at baseline
b P-value for trend